Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Expenses: 2020-2024

Historic Operating Expenses for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $99.8 million.

  • Taysha Gene Therapies' Operating Expenses rose 22.89% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.4 million, marking a year-over-year increase of 11.01%. This contributed to the annual value of $99.8 million for FY2024, which is 13.54% up from last year.
  • As of FY2024, Taysha Gene Therapies' Operating Expenses stood at $99.8 million, which was up 13.54% from $87.9 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Operating Expenses peaked at $173.3 million during FY2021, and registered a low of $43.0 million during FY2020.
  • In the last 3 years, Taysha Gene Therapies' Operating Expenses had a median value of $99.8 million in 2024 and averaged $117.5 million.
  • In the last 5 years, Taysha Gene Therapies' Operating Expenses surged by 302.93% in 2021 and then crashed by 46.72% in 2023.
  • Over the past 5 years, Taysha Gene Therapies' Operating Expenses (Yearly) stood at $43.0 million in 2020, then spiked by 302.93% to $173.3 million in 2021, then declined by 4.80% to $164.9 million in 2022, then slumped by 46.72% to $87.9 million in 2023, then rose by 13.54% to $99.8 million in 2024.